pepmg_

● Evidence first · market data second

Explore the research.
Compare the market.

Find a compound, read the published evidence and reported study doses, then compare vendor prices and transparency signals. Every listing and source keeps its context.

Names and aliases work: retatrutide, GLP-3 RT, BPC-157.

01Browse all compoundsFilter the index and open research, studies, and prices 02Read the researchEvidence reviews, study summaries, and source links 03Compare tracked pricesRanked by normalized $/mg—not by commission 04Open the reconstitution calculatorConcentration math with units and assumptions shown

● Research desk

Field Notes

View all →
Evidence audit · 10 min

Melanotan II's published controlled trials enrolled 23 men, the last in 2000. An FDA panel is due to consider it by February 2027.

Read → Evidence audit · 12 min

ARA-290's largest trial met its primary endpoint. The endpoint was nerve fibers in the eye.

Read →

● Definitive compound dossiers

One page, from literature to price comparisons.

Browse all compounds →
01GLP-1 / triple agonist

Retatrutide

Moderate evidenceevidence label

$2.02/mgsnapshot floor

30vendors

26/30publish a COA, 18 openable at a lab

Open complete dossier →
02Repair peptide

BPC-157

Preclinical onlyevidence label

$1.30/mgsnapshot floor

88vendors

78/88publish a COA, 54 openable at a lab

Open complete dossier →
03GLP-1 / GIP dual agonist

Tirzepatide

Strong evidenceevidence label

$1.35/mgsnapshot floor

31vendors

27/31publish a COA, 16 openable at a lab

Open complete dossier →

COA availability means a vendor publishes a document or index we can link. It does not mean pepmg certified the product, batch, safety, or authenticity.

● Seven-day market intelligence

The index is a living dataset.

Full change log →

Largest real price drop

GHRP-6 ↓51%

$10.40 → $5.10/mg at Sports Technology Labs

Widest price spread

18.5×

GLP2 TZ · $1.35–$25.00/mg

New listings

36

added in the last 7 days

Start with a full dossier

Retatrutide

research, regulatory status, 30 vendors, and source receipts

● The credibility contract

Useful enough to rely on. Honest enough not to push.

Full disclosure →
01

Ranking is deterministic

Eligible rows sort by normalized $/mg. Affiliate commission is never an input.

02

Money is visible

Any link that ever pays pepmg is labeled beside the action, and commission never touches ranking. Non-paying rows are always visible too.

03

Claims carry evidence labels

Human, animal, and in-vitro findings are not collapsed into one vague “research-backed” claim.

04

Sources keep their limits

A vendor-hosted COA is linked and classified, never promoted as proof of safety or authenticity.

● Weekly market briefing

Follow changes in the price index.

Real repricings, new market floors, and meaningful source changes—without sponsored placements.